Biopharma revenues key to Pall’s Q3 gains
Sales to the biopharmaceutical sector drove revenue growth at Pall in third quarter fiscal 2011 and will be key to the firm’s future says CEO.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs